Evidence map›Paper›PMID 32745521›Full record

ArticleNeurobiology of disease2020

Accelerated transsulfuration metabolically defines a discrete subclass of amyotrophic lateral sclerosis patients.

Qiuying Chen, Csaba Konrad, Davinder Sandhu, Dipa Roychoudhury, Benjamin I Schwartz, Roger R Cheng, Kirsten Bredvik, Hibiki Kawamata, Elizabeth L Calder, Lorenz Studer and 3 more

Open access · goldAbstract read
In one paragraph

Article in Neurobiology of disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Qiuying ChenDepartment of Pharmacology, Weill Cornell Medicine, New York, NY, USA.
Csaba KonradBrain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.
Davinder SandhuDepartment of Pharmacology, Weill Cornell Medicine, New York, NY, USA.
Dipa RoychoudhuryAgilent Technologies, Santa Clara, CA, USA.
Benjamin I SchwartzDepartment of Pharmacology, Weill Cornell Medicine, New York, NY, USA.
Roger R ChengDepartment of Pharmacology, Weill Cornell Medicine, New York, NY, USA.
Kirsten BredvikBrain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.
Hibiki KawamataBrain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.
Elizabeth L CalderThe Center for Stem Cell Biology, Sloan-Kettering Institute for Cancer Center, New York, NY, USA.
Lorenz StuderThe Center for Stem Cell Biology, Sloan-Kettering Institute for Cancer Center, New York, NY, USA.
Steven M FischerAgilent Technologies, Santa Clara, CA, USA.
Giovanni ManfrediBrain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA. Electronic address: gim2004@med.cornell.edu.
Steven S GrossDepartment of Pharmacology, Weill Cornell Medicine, New York, NY, USA. Electronic address: ssgross@med.cornell.edu.
Cornell University · USAgilent Technologies (United States) · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Mitochondria quality control in SOD1-ALSR01NS062055 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI MANFREDI, GIOVANNI · 2009 to 2019
$3.7M
Metabolic profiling of sporadic ALS patients: from fibroblasts to neurons and backR01NS093872 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI GROSS, STEVEN S, MANFREDI, GIOVANNI · 2015 to 2019
$2.7M
NCI NIH HHS P30 CA008748NINDS NIH HHS R01 NS062055NINDS NIH HHS R01 NS093872
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis is a disease characterized by progressive paralysis and death. Most ALS-cases are sporadic (sALS) and patient heterogeneity poses challenges for effective therapies. Applying metabolite profiling on 77-sALS patient-derived-fibroblasts and 43-controls, we found ~25% of sALS cases (termed sALS-1) are characterized by transsulfuration pathway upregulation, where methionine-derived-homocysteine is channeled into cysteine for glutathione synthesis. sALS-1 fibroblasts selectively exhibited a growth defect under oxidative conditions, fully-rescued by N-acetylcysteine (NAC). [U

Indexed as

MetabolomeAgedAmyotrophic Lateral SclerosisCase-Control StudiesCells, CulturedCysteineFemaleFibroblastsGlucoseGlutathioneHumansMaleMetabolic Networks and PathwaysMetabolomicsMiddle AgedSerineCysteineGlucoseGlutathioneSerineCysteineDisease stratificationMetabolomicsMethionineSporadic amyotrophic lateral sclerosisStable isotope tracingTranssulfuration

Identifiers

PMID32745521
PMCPMC7491150
OpenAlexW3046589774

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.